| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 7,803,131 | 6,079,488 |
| Net increase/(decrease) in cash | 2,200,089 | 2,357,415 |
| Cash and cash equivalents at beginning of period | 3,706,713 | - |
| Cash and cash equivalents at end of period | 5,906,802 | - |
Acurx Pharmaceuticals, Inc. (ACXP)
Acurx Pharmaceuticals, Inc. (ACXP)